Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint, with top-line results...
-
PHOENIX, Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President,...
-
ROCKVILLE, MD, Oct. 22, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
-
VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- The following issues have been halted by IIROC / L’OCRCVM a suspendu la négociation des titres suivants : Company / Société :Pivot...
-
The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and other efficacy...
-
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James...
-
SALT LAKE CITY, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® test...
-
Sunnyvale, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, launches a fully automated allergy testing portal for doctors and...
-
AMES, Iowa, Oct. 18, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018....
-
Granted claims cover both oral and injectable formulations of RigosertibNewly issued US patent 10,098,862 extends protection for Rigosertib into 2037Equivalent coverage is being sought worldwide and,...